Literature DB >> 9262512

Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake.

R Gagnemo-Persson1, A Samuelsson, R Hâkanson, P Persson.   

Abstract

Treatment with omeprazole, a long-acting proton pump inhibitor of acid secretion, induces hypergastrinemia. In chickens, omeprazole induces growth not only of the acid-producing mucosa (probably reflecting the trophic action of gastrin), but also of the parathyroid glands (hypertrophy + hyperplasia), while suppressing bone density and body weight gain without affecting blood calcium. The first part of the present study was concerned with the effect of omeprazole, ergocalciferol (vitamin D2), and restricted food intake on the gene expression of parathyroid hormone (PTH) in the parathyroid glands of the chicken. Chickens were treated with omeprazole (400 micromol/kg/day, I.M.), food restriction, omeprazole + food restriction, ergocalciferol (250 000 IU/kg/day, S.C.), or ergocalciferol + omeprazole for 5 weeks. The weight gain of the chickens was monitored, and the weights of the parathyroid glands and femurs were determined at sacrifice. PTH mRNA in the parathyroid glands was analyzed by Northern blot. The second part of the study examined the effect of 3 weeks of continuous gastrin infusion (chicken gastrin 20-36, 5 nmol/kg/hour, S.C.) on the expression of PTH mRNA in the parathyroid glands. Omeprazole reduced the body weight and femur density (ash weight per volume) while greatly increasing the weight of the parathyroid glands and the PTH gene expression. Food restriction alone and ergocalciferol alone (at a dose that raised blood Ca2+) were without effect, but food restriction greatly enhanced the omeprazole-evoked increase in parathyroid gland weight and PTH gene expression. Gastrin increased the weight of the parathyroid glands and reproduced the effect of omeprazole on PTH gene expression. Hence, it seems likely that the effect of omeprazole reflects the ensuing hypergastrinemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9262512     DOI: 10.1007/s002239900325

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  16 in total

1.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.

Authors:  Douglas A Corley; Ai Kubo; Wei Zhao; Charles Quesenberry
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 2.  Chronic proton pump inihibitor therapy and calcium metabolism.

Authors:  Yu-Xiao Yang
Journal:  Curr Gastroenterol Rep       Date:  2012-12

3.  Proton Pump Inhibitor Use, H2-Receptor Antagonist Use, and Risk of Incident Clinical Vertebral Fracture in Women.

Authors:  Julie M Paik; Harold N Rosen; Catherine M Gordon; Gary C Curhan
Journal:  Calcif Tissue Int       Date:  2018-05-12       Impact factor: 4.333

4.  Weight gain in mice on a high caloric diet and chronically treated with omeprazole depends on sex and genetic background.

Authors:  Milena Saqui-Salces; Amy C Tsao; Merritt G Gillilland; Juanita L Merchant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-11-03       Impact factor: 4.052

5.  Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis.

Authors:  Si-Dong Yang; Qian Chen; Hai-Kun Wei; Feng Zhang; Da-Long Yang; Yong Shen; Wen-Yuan Ding
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 6.  Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

7.  Bone density in proton pump inhibitors users: a prospective study.

Authors:  Kamil Ozdil; Resul Kahraman; Abdurrahman Sahin; Turan Calhan; Erdem H Gozden; Umit Akyuz; Burak Erer; Mehmet H Sokmen
Journal:  Rheumatol Int       Date:  2013-03-02       Impact factor: 2.631

8.  Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population-based nested case-control study.

Authors:  S Kumar; M T Drake; C D Schleck; M L Johnson; J A Alexander; D A Katzka; P G Iyer
Journal:  Aliment Pharmacol Ther       Date:  2017-10-05       Impact factor: 8.171

9.  Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.

Authors:  Hamed Khalili; Edward S Huang; Brian C Jacobson; Carlos A Camargo; Diane Feskanich; Andrew T Chan
Journal:  BMJ       Date:  2012-01-30

10.  Proton Pump Inhibitors and the Risk of Early Aseptic Loosening in Hip and Knee Arthroplasty.

Authors:  Iskandar Tamimi; Pablo Carnero; David Bautista; David Gonzalez; Pablo Rodrigo; María Jose Bravo; Abel Gómez; Faleh Tamimi; David Garcia de Quevedo
Journal:  Geriatr Orthop Surg Rehabil       Date:  2022-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.